CORPORATE ACCESS

Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company...

LOS ANGELES - The following is issued on behalf of ChromaDex (NASDAQ: CDXC). Dear Fellow Shareholders: I want to take this opportunity to provide an update on ChromaDex's intellectual property portfolio, as well as perspective on why our business is not impacted by a...

This first-of-its-kind human clinical study in AD patients showcased CMA supplementation significantly improved cognitive function and associated biomarkers LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced...

NR improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in first-ever five-month-long study in monozygotic twin pairs LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy...

Globally acclaimed authority on aging to further research on the potential benefits of nicotinamide riboside (NR) and age-related conditions. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has...

LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance /...

Results from this study on healthy subjects support previous research demonstrating that NR supplementation may impact neurodegenerative biomarkers commonly associated with aging LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to...

U.S. FDA declares NMN ingredient may not be sold or marketed as a dietary supplement in the U.S. since first investigated as a drug LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4,...

Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 million and $1.2 million, respectively, for the three months ended September 30, 2022. LOS ANGELES - ChromaDex Corp....

LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss its financial results for the third quarter,...